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Patients with type 2 diabetes are at increased mortality risk,
mainly because of cardiovascular disease (1). On the basis of
the evidence that a pharmacological approach against hy-
pertension, dyslipidemia, and hyperglycemia is needed to
tackle this devastating clinical outcome (2), such patients
are usually aggressively treated. In the U.S., prescribed retail
pharmaceutical spending accounted for approximately half
of the annual diabetes cost, which approximated $100 bil-
lion in 2013 (3). How long will we be able to cope with such
a burden, especially considering it is likely to increase over
the next decades (4)? Under this scenario, it is both ethical
and smart to pay attention to the costs.
In treating hyperglycemia we are facing a tendency, partly
driven by pressure from pharmaceutical companies, to
abandon the old, well-known, and cheap sulfonylureas in
favor of new and costly glucose-lowering molecules. One of
the reasons given is that there is a deleterious effect of
sulfonylureas on cardiovascular disease suggested by various
observational studies but never proven by randomized clin-
ical trials (5–7), the gold standard approach for addressing
similar issues. Unfortunately, as sulfonylureas entered the
market long before the U.S. Food and Drug Administration
request of cardiovascular risk assessment for novel antidia-
betes drugs to be approved (8), an adequately powered car-
diovascular trial on sulfonylurea therapy is not available.
One should, therefore, wonder if the mantra of cardiovas-
cular deleterious effects of this class of drugs is destined to
last forever.
Recently, genetic studies have been appropriately de-
signed to get deeper insights on on-target drug pleiotropic
effects, such as that of GLP-1 agonists on cardiovascular
outcomes (9) or that of statins on the risk of type 2 diabetes
(10). Along this line, the study by Emdin et al. (11) in this
issue of Diabetes adds important, and somehow reassuring,
evidence on the cardiovascular effect of sulfonylureas.
The common p.A1369S nonsynonymous polymorphism
in ABCC8 (the gene encoding for SUR1, a component of the
sulfonylurea receptor) was used as a naturally occurring
model of SUR1 activation to test for an association with
coronary heart disease (CHD) in 120,286 participants from
the UK Biobank and in summary data from several previous
genome-wide association studies. In addition, the authors
investigated the association with type 2 diabetes and vari-
ous cardiometabolic traits. Data obtained by this intelligent
study design clearly show that the p.A1369S amino acid
change, previously known 1) to mimic in vitro the pharma-
cological effects of sulfonylureas by promoting closure of
the ATP-sensitive potassium channel (12), 2) to increase in
vivo insulin secretion (13), and 3) to protect from type 2
diabetes (13,14), was in fact associated with a reduced risk
of CHD and a composite cardiovascular end point, including
stroke, heart failure, and peripheral vascular disease (per
allele reduction equal to 2% and 3%, respectively). Each
copy of the p.A1369S variant was also associated with a
7% lower risk of type 2 diabetes, thus replicating previous
findings (13). This makes it possible to calculate that per
10% reduction in type 2 diabetes risk the ABCC8 p.A1369S
variant exerts a 4% reduction on CHD risk. Such a relation-
ship is very similar to that reported for a missense
variant in GLP1R, encoding the GLP-1 receptor, the specific
target of GLP-1 agonists, which—notably, in our specific
context—have been recently reported to be cardioprotec-
tive (15,16).
Although association studies cannot provide definite
mechanistic evidences, one cannot avoid asking how ABCC8
p.A1369S exerts such positive effect on cardiovascular out-
comes. Considering that SUR1 is mostly expressed in brain,
pancreatic (a, b, and d), and other neuroendocrine cells
(17), it is unlikely that ABCC8 p.A1369S acts directly on
the vasculature and heart.
By referring to previous studies addressing the role of
genetic predisposition of diabetes on the risk of CHD (18),
Emdin et al. (11) suggest that the cardioprotective effect of
p.A1369S variant is based on more than just diabetes risk
reduction. Although this is an intriguing possibility, it re-
mains truly impossible to determine whether and to what
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extent the two favorable outcomes are independent or,
conversely, somehow interwoven. An alternative hypothesis
comes from data on adiposity measures, with the p.A1369S
variant being associated with an expected increased BMI
(6,7) but also an unexpected lower BMI-adjusted waist-
to-hip ratio, an established marker of reduced risk for
both type 2 diabetes and CHD (19). Whether a favorable
nonabdominal fat accumulation has played a role on the
cardioprotective effect of ABCC8 p.A1369S and whether
such an effect is observed also under sulfonylurea treat-
ment are questions that remain unanswered. A schematic
view of possible pleiotropic effects of the p.A1369S gain-of-
function amino acid change on cardiometabolic traits is
shown in Fig. 1.
As Emdin et al. (11) admit and clearly discuss, their
study has some limitations. First, although the effect of
ABCC8 p.A1369S on CHD has been tested in the general
population, the cardiovascular effect of sulfonylureas, if
any, would occur in patients with diabetes, who are aggres-
sively treated and intrinsically prone to CHD. Investigating
the association between ABCC8 p.A1369S and CHD among
patients with diabetes is the only way to understand
whether the encouraging finding of Emdin et al. is extend-
able to type 2 diabetes. Second, the length and degree of
SUR1 stimulation are very different depending on whether
it is due to ABCC8 p.A1369S or to exogenous sulfonylurea
administration, with the former being lifelong and mild and
the latter initiating in adult life and being definitively more
dramatic. For example, in patients with type 2 diabetes,
treatment with sulfonylureas is a main cause of severe hypo-
glycemic episodes, which are believed to increase cardiovascular
risk (20). The genetic tool used to recapitulate sulfonylurea-
mediated SUR1 stimulation certainly does not capture this
drug side effect. Third, it cannot be totally excluded that
sulfonylureas also have off-target (i.e., not mediated by
SUR1) cardiovascular effects, which, by definition, cannot
be replicated by a genetic variant affecting SUR1.
In all, although the above-mentioned limitations call
for caution in interpreting and generalizing the reported
results, the study by Emdin et al. (11) does question the
mantra of sulfonylureas as burdened by cardiovascular side
effects, a relevant issue for the entire diabetes community.
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Figure 1—Pleiotropic effects of naturally occurring SUR1 gain-of-function amino acid change on cardiometabolic traits. The ATP-sensitive
potassium channel is composed by SUR1, encoded by ABCC8, and the selective potassium pore Kir6.2, encoded by KCNJ11. The SUR1
p.A1369S is a gain–of-function amino acid change, which mimics in vitro the effects of sulfonylureas by promoting the closure of ATP-sensitive
potassium channel (12) that ensues in increasing potassium efflux, cell membrane depolarization, calcium influx and promoting insulin exo-
cytosis in pancreatic b-cells. In humans, the p.A1369S variant has been associated with enhanced glucose-induced insulin secretion (13) and
reduced risk of type 2 diabetes (13,14). Emdin et al. (11) showed that the SUR1 p.A1369S variant is also associated with lower risk of CHD. The
intimate biology underlying this association is not known. One possibility is that the SUR1 p.A1369S variant affects the risk of CHD, at least
partly, via its protective effect on type 2 diabetes, a major cardiovascular risk factor. It is also possible that the reduced risk of CHD is a
consequence of the unexpected and difficult-to-understand reduced abdominal adiposity shown by carriers of SUR1 p.A1369S. Finally, SUR1 is
mostly expressed in brain, pancreatic, and neuroendocrine cells (17), which are unlikely to be involved in shaping cardiovascular risk. However, it
cannot be entirely excluded that part of p.A1369S cardioprotective effect is mediated by low, though physiologically relevant, expression of
SUR1 in other tissues. T2D, type 2 diabetes; WHR, waist-to-hip ratio.
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